Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
The Cancer Letter's weekly podcast of interviews, discussions, and more to dig deep into the issues that shape oncology.
New episodes every Wednesday.
SUBSCRIBE ON
Spotify Apple Podcast YouTube
Spotify Apple Podcast YouTube
on air
The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology
PodcastThe Directors

The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology
“Even when funding gets restored and if the H-1B visa threat doesn’t materialize, it creates an environment where especially young people become uncertain.”

October 10, 2025
Vol.51 No.37
By Claire Marie Porter and Paul Goldberg
Pulitzer-winning healthcare reporter Laurie McGinley on her shift to advocacy work with PACR
Podcast

Pulitzer-winning healthcare reporter Laurie McGinley on her shift to advocacy work with PACR

October 08, 2025
Vol.51 No.36
With Anthony Letai’s appointment, NCI is now under new leadership—just in time for a shutdown
Podcast

With Anthony Letai’s appointment, NCI is now under new leadership—just in time for a shutdown

October 01, 2025
Vol.51 No.35
Congress seems to have NCI’s back—is cautious optimism warranted? Two former directors say yes.
Podcast

Congress seems to have NCI’s back—is cautious optimism warranted? Two former directors say yes.

September 24, 2025
Vol.51 No.34
Jonathan Mahler on his front-page story in the NYT Magazine on Trump’s deliberate dismantling of America’s War on Cancer
Podcast

Jonathan Mahler on his front-page story in the NYT Magazine on Trump’s deliberate dismantling of America’s War on Cancer

September 17, 2025
Vol.51 No.33
The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
PodcastThe Directors

The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.”

September 12, 2025
Vol.51 No.33
By Claire Marie Porter, Jacquelyn Cobb and Paul Goldberg
On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed
Podcast

On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed

September 10, 2025
Vol.51 No.32
Robert A. Winn on his new vision to train cancer center leaders: “I had a big bold idea and an ‘Aha!’ moment.”
Podcast

Robert A. Winn on his new vision to train cancer center leaders: “I had a big bold idea and an ‘Aha!’ moment.”

September 03, 2025
Gardiner Harris, acclaimed health care and pharma journalist, on his New York Times bestselling book
Podcast

Gardiner Harris, acclaimed health care and pharma journalist, on his New York Times bestselling book

August 27, 2025
Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Conversation with The Cancer LetterFreePodcast

Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group

August 14, 2025
Vol.51 No.32
By Paul Goldberg and Sara Willa Ernst

Posts navigation

Previous123456…8Next

Trending Stories

  • Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
  • Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
  • Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)
  • One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
  • As more people are surviving cancer, we must continue funding bold science
  • GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
    Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account